- Home
- RFMZ vs KRRO Comparison
RFMZ vs KRRO Comparison
Compare RFMZ & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFMZ
- KRRO
- Stock Information
- Founded
- RFMZ 2021
- KRRO 2014
- Country
- RFMZ United States
- KRRO United States
- Employees
- RFMZ N/A
- KRRO N/A
- Industry
- RFMZ Trusts Except Educational Religious and Charitable
- KRRO Biotechnology: Pharmaceutical Preparations
- Sector
- RFMZ Finance
- KRRO Health Care
- Exchange
- RFMZ Nasdaq
- KRRO Nasdaq
- Market Cap
- RFMZ 314.9M
- KRRO 358.3M
- IPO Year
- RFMZ N/A
- KRRO 2019
- Fundamental
- Price
- RFMZ $12.85
- KRRO $42.15
- Analyst Decision
- RFMZ
- KRRO Strong Buy
- Analyst Count
- RFMZ 0
- KRRO 7
- Target Price
- RFMZ N/A
- KRRO $96.71
- AVG Volume (30 Days)
- RFMZ 76.6K
- KRRO 293.5K
- Earning Date
- RFMZ 01-01-0001
- KRRO 11-11-2025
- Dividend Yield
- RFMZ 7.43%
- KRRO N/A
- EPS Growth
- RFMZ N/A
- KRRO N/A
- EPS
- RFMZ 0.65
- KRRO N/A
- Revenue
- RFMZ N/A
- KRRO $6,281,000.00
- Revenue This Year
- RFMZ N/A
- KRRO $116.91
- Revenue Next Year
- RFMZ N/A
- KRRO N/A
- P/E Ratio
- RFMZ $21.49
- KRRO N/A
- Revenue Growth
- RFMZ N/A
- KRRO N/A
- 52 Week Low
- RFMZ $11.28
- KRRO $10.29
- 52 Week High
- RFMZ $14.57
- KRRO $85.00
- Technical
- Relative Strength Index (RSI)
- RFMZ 40.12
- KRRO 53.33
- Support Level
- RFMZ $12.97
- KRRO $40.70
- Resistance Level
- RFMZ $13.25
- KRRO $55.89
- Average True Range (ATR)
- RFMZ 0.13
- KRRO 6.01
- MACD
- RFMZ -0.04
- KRRO -0.73
- Stochastic Oscillator
- RFMZ 6.98
- KRRO 13.40
About RFMZ RiverNorth Flexible Municipal Income Fund II Inc.
RiverNorth Flex Muni Income Fund II Inc is a diversified, closed-end management investment company. Its primary investment objective is to seek current income exempt from regular U.S. federal income taxes. The fund's secondary investment objective is total return.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.